scholarly journals Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study

Oncology ◽  
2018 ◽  
Vol 94 (5) ◽  
pp. 274-280 ◽  
Author(s):  
Soham D. Puvvada ◽  
José M. Guillén-Rodríguez ◽  
Jessica Yan ◽  
Lora Inclán ◽  
Kara Heard ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin Lymphoma ◽  
Yttrium 90

scholarly journals Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology

2017 ◽  
Vol 23 (6) ◽  
pp. 922-929 ◽  
Author(s):  
Amrita Y. Krishnan ◽  
Joycelynne Palmer ◽  
Auayporn P. Nademanee ◽  
Robert Chen ◽  
Leslie L. Popplewell ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
High Dose ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin Lymphoma ◽  
Yttrium 90

scholarly journals Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma

2009 ◽  
Vol 100 (10) ◽  
pp. 1951-1956 ◽  
Author(s):  
Kensei Tobinai ◽  
Ken-ichi Ishizawa ◽  
Michinori Ogura ◽  
Kuniaki Itoh ◽  
Yasuo Morishima ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Non Hodgkin Lymphoma

High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351

2007 ◽  
Vol 48 (5) ◽  
pp. 870-880 ◽  
Author(s):  
Bruce A. Peterson ◽  
Jeffrey Johnson ◽  
Margaret A. Shipp ◽  
Maurice Barcos ◽  
Jon P. Gockerman ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Initial Treatment ◽  
Phase Ii Study ◽  
High Dose ◽  
Non Hodgkin Lymphoma ◽  
Group B ◽  
Leukemia Group

Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3703-3703
Author(s):  
Jae-Cheol Jo ◽  
Dok Hyun Yoon ◽  
Shin Kim ◽  
Seongsoo Jang ◽  
Chan-Jeoung Park ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Efficacy And Safety ◽  
Event Free Survival ◽  
Ibritumomab Tiuxetan ◽  
Free Survival ◽  
Non Hodgkin Lymphoma ◽  
Yttrium 90

Abstract Abstract 3703 Background: Currently, there are accumulating data on the role of radioimmunotherapy in autologous stem cell transplantation (ASCT) with promising results. We compared the efficacy and safety of yttrium-90-ibritumomab tiuxetan (90Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (BuCyE) with those of BuCyE alone followed by ASCT in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods: From October 2005 to May 2011, 71 NHL patients underwent high-dose chemotherapy with BuCyE (n=52) or 90Y-ibritumomab plus BuCyE (n=19) followed by ASCT at the Asan Medical Center. Of 52 patients receiving BuCyE, we found 19 patients who had B-cell NHL and they comprised control group of BuCyE alone (n=19). Retrospective comparison matched by the same IPI was performed for the efficacy and safety between two groups. Results: The patient cohort consisted of 38 individuals (19 males), of median age 52 years (range, 27–65 years). The baseline characteristics were well balanced between the two groups. The median time to platelet engraftment (>20,000/mm3) and the median time to neutrophil engraftment (>500/mm3) did not differ between 90Y-ibritumomab plus BuCyE (12 days [range, 3–103 days] and 10 days [range, 8–12 days], respectively) and BuCyE alone (12 days [range, 8–35 days] and 10 days [range, 9–12 days], respectively). The objective overall response rate was 89.5% (17/19): continued CR, 42.1% (8/19); induced CR, 36.8% (7/19); PR, 10.5% (2/19) in 90Y-ibritumomab plus BuCyE group, and 78.9% (15/19): continued CR, 26.3% (5/19); induced CR, 47.4% (9/19); PR, 5.3% (1/19) in BuCyE group, respectively (p =0.649). Median follow-up duration for survivors was 30 months. Event-free survival tended to be better in 90Y-ibritumomab plus BuCyE group with a median event-free survival duration of 12.5 months in 90Y-ibritumomab plus BuCyE group and 6.2 months in BuCyE group (p =0.236) (figure 1-a).There seemed to be no significant difference in overall survival between the two groups (p =0.767, figure 1-b). The toxicities including the incidence of grade 3 or higher stomatitis, nausea, vomiting, diarrhea, hyperbilirubinemia were similar in the two groups. Conclusion: Addition of 90Y-ibritumomab to BuCyE high-dose chemotherapy may potentially benefit patients with relapsed or refractory B-cell NHL at no cost of additional toxicity, which warrants further investigation. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document